Sclerostin modulation holds promise for dental indications

Mohamed G. Hassan, Abbas R. Zaher, Juan Martin Palomo, Leena Palomo

Research output: Contribution to journalReview articlepeer-review


Sclerostin modulation is a novel therapeutic bone regulation strategy. The anti-sclerostin drugs, proposed in medicine for skeletal bone loss may be developed for jaw bone indications in dentistry. Alveolar bone responsible for housing dentition share common bone remodeling mechanisms with skeletal bone. Manipulating alveolar bone turnover can be used as a strategy to treat diseases such as periodontitis, where large bone defects from disease are a surgical treatment challenge and to control tooth position in orthodontic treatment, where moving teeth through bone in the treatment goal. Developing such therapeutics for dentistry is a future line for research and therapy. Furthermore, it underscores the interprofessional relationship that is the future of healthcare.

Original languageEnglish (US)
Article number134
JournalHealthcare (Switzerland)
Issue number4
StatePublished - Dec 2018


  • Alveolar bone
  • Anti-sclerostin
  • Bone loss
  • Bone remodeling
  • Orthodontic
  • Periodontitis
  • Sclerostin
  • Tooth movement

ASJC Scopus subject areas

  • Leadership and Management
  • Health Policy
  • Health Informatics
  • Health Information Management


Dive into the research topics of 'Sclerostin modulation holds promise for dental indications'. Together they form a unique fingerprint.

Cite this